Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-1081-2026

Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80 Recall

Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80 Model/Catalog Number: 5081288; 5081289 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A

FDA recall Class II

Ongoing

FDA lists this Class II recall for Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-1081-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Dec 9, 2025
FDA report date
Jan 21, 2026
Quantity in commerce
Not reported
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80 Model/Catalog Number: 5081288; 5081289 Software Version: N/A Product Description: Radiopaque, poly(methyl methacrylate)-based (PMMA) bone cement, pre-filled into a mixing and application system, suitable for use with or without vacuum (ready to mix). Component: N/A

Affected model & UDI checker

Search the exact identifiers published for Z-1081-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
5081288Brand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80Check source noticeNot specified
Not specifiedBrand Name: PALACOS Product Name: PALACOS R+G pro 40; PALACOS R+G pro 80Check source notice04260102136182
FDA code information

Lot Code: UDI-DI: 04260102136182; 04260102136212

View the original FDA recall notice

Why was this product recalled?

increase of complaints regarding the breakage of the ampoules within their device systems. An extensive investigation revealed that multiple factors have an impact on the ampoule breakage. An unfortunate combination of these influence factors can lead to unbreakable ampoules. If none or not all ampoules break, the product cannot be used on the patient since no or no appropriate cement dough is formed.

What actions did Heraeus Medical GmbH (Dental Division) take?

On December 9, 2025 Urgent Field Safety Notice emails were sent to customers. Actions to be taken: 1. Read this Field Safety Notice and ensure that all relevant hospital departments are informed about its content. 2. Please complete the attached customer reply form and send it to hm.fsca.medical@heraeus.com within five (5) calendar days. This form must be returned even if you no longer use the device. 3. Keep a copy of the attached customer reply form with your records in the event of a compliance audit of your facility. 4. Heraeus Medical GmbH is fully cooperating with regulatory authorities and is committed to resolving this issue efficiently. For further details regarding this field safety notice, please contact your Heraeus Medical sales representative or distributor. We regret any inconvenience caused by this action and value your cooperation and commitment to patient safety. This field safety notice was submitted to the FDA in context of the correction authority report.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology